Given the current lack of disease-modifying therapies for dysferlinopathies, ASO-mediated exon skipping has shown potential in bypassing disease-causing pathogenic variants to generate a truncated dysferlin protein with enhanced functionality [97]. Here, DYSF is linked to neuromuscular disease caused by qualitative or quantitative defects of dysferlin.